| 英文名称 |
中文名称 |
CAS号 |
操作 |
| TGX-221 |
(+/-)-7-甲基-2-(吗啉-4-基)-9-(1-苯基氨基乙基)吡啶并[1,2-A]嘧啶-4-酮 |
663619-89-4 |
详细
|
| PHA-767491(HCl) |
PHA767491 |
845714-00-3 |
详细
|
| Ganetespib |
GANETESPIB |
888216-25-9 |
详细
|
| Moclobemide (Ro 111163) |
吗氯贝胺 |
71320-77-9 |
详细
|
| Ulocuplumab |
Ulocuplumab |
1375830-34-4 |
详细
|
| Brontictuzumab |
Brontictuzumab |
1447814-75-6 |
详细
|
| Research Grade Obexelimab |
奥贝利单抗 |
1690307-05-1 |
详细
|
| Vandortuzumab Vedotin |
Vandortuzumab Vedotin |
1471985-92-8 |
详细
|
| Amivantamab |
AMIVANTAMAB (埃万妥单抗 ) |
2171511-58-1 |
详细
|
| GSK 429286A |
N-(6-氟-1H-吲唑-5-基)-2-甲基-6-氧代-4-[4-(三氟甲基)苯基]-1,4,5,6-四氢-3-吡啶甲酰胺 |
864082-47-3 |
详细
|
| Sparsentan |
4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 |
254740-64-2 |
详细
|
| VR23 |
VR23 |
1624602-30-7 |
详细
|
| Anetumab Ravtansine |
Anetumab Ravtansine |
1375258-01-7 |
详细
|
| Fletikumab |
夫来库单抗 |
1357158-22-5 |
详细
|
| Abituzumab |
Abituzumab |
1105038-73-0 |
详细
|
| Lenzilumab |
Lenzilumab |
1229575-09-0 |
详细
|
| Research Grade Tafasitamab |
TAFASITAMAB (ANTI-CD19) |
1422527-84-1 |
详细
|
| CID 755673 |
2,3,4,5-Tetrahydro-7-hydroxy-1H-benzofuro[2,3-c]azepin-1-one |
521937-07-5 |
详细
|
| HMN-214 |
(E)-4-[2-[2-[N-乙酰基-N-[(4-甲氧基苯基)磺酰]氨基]苯基]乙烯基]吡啶 1-氧化物 |
173529-46-9 |
详细
|
| LMK-235 |
N-[[6-(羟基氨基)-6-氧代己基]氧基]-3,5-二甲基-苯甲酰胺 |
1418033-25-6 |
详细
|
| SB 366791 |
3-(4-氯苯基)-N-(3-甲氧基苯基)-2-丙烯酰胺 |
472981-92-3 |
详细
|
| Tirzepatide |
替尔泊肽 |
2023788-19-2 |
详细
|
| Tarextumab |
Tarextumab |
1359940-55-8 |
详细
|
| Anifrolumab |
Anifrolumab |
1326232-46-5 |
详细
|
| Emibetuzumab |
Emibetuzumab |
1365287-97-3 |
详细
|
| Lumretuzumab |
Lumretuzumab |
1448327-63-6 |
详细
|
| SKF38393 HCl |
SKF38393 HCL |
62717-42-4 |
详细
|
| Eldelumab |
Eldelumab |
946414-98-8 |
详细
|
| Ralpancizumab |
Ralpancizumab |
1407495-04-8 |
详细
|
| Denintuzumab Mafodotin |
Denintuzumab Mafodotin |
1399672-02-6 |
详细
|
| Lacutamab |
LACUTAMAB (拉可妥单抗 ) |
2187368-16-5 |
详细
|
| semaglutide |
司美格鲁肽 |
99291-20-0 |
详细
|
| GW0742 |
GW0742 |
317318-84-6 |
详细
|
| A66 |
A66 |
1166227-08-2 |
详细
|
| Apoptozole |
BenzaMide, 4-[[2-[3,5-bis(trifluoroMethyl)phenyl]-4,5-bis(4-Methoxyphenyl)-1H-iMidazol-1-yl]Methyl]- |
1054543-47-3 |
详细
|
| APS-2-79 |
APS-2-79 盐酸盐 |
2002381-31-7 |
详细
|
| mu-conotoxin |
芋螺肽 |
936616-33-0 |
详细
|
| AG 490 |
酪氨酸磷酸化抑制剂AG 490 |
133550-30-8 |
详细
|
| Dapirolizumab Pegol |
Dapirolizumab Pegol |
1416147-64-2 |
详细
|
| Coltuximab Ravtansine |
Coltuximab Ravtansine |
1269764-99-9 |
详细
|
| Firivumab |
Firivumab |
1443004-15-6 |
详细
|
| Lokivetmab |
Lokivetmab |
1533403-95-0 |
详细
|
| Kartogenin |
2-([1,1-联苯]-4-基氨基甲酰)苯甲酸 |
4727-31-5 |
详细
|
| Oprozomib;ONX-0912 |
ONX0912 |
935888-69-0 |
详细
|
| FPS-ZM1 |
N-BENZYL-4-CHLORO-N-CYCLOHEXYLBENZAMIDE |
945714-67-0 |
详细
|
| KC7F2 |
KC7F2 |
927822-86-4 |
详细
|
| HLCL-61 |
HLCL-61 盐酸盐 |
1158279-20-9 |
详细
|
| Avelumab |
阿维鲁单抗 |
1537032-82-8 |
详细
|
| Reversine |
REVERSINE |
656820-32-5 |
详细
|
| Scriptaid |
SCRIPTAID |
287383-59-9 |
详细
|
| Tovetumab |
Tovetumab |
1243266-04-7 |
详细
|
| Enfortumab Vedotin |
维汀-恩弗妥单抗 |
1346452-25-2 |
详细
|
| Pasotuxizumab |
Pasotuxizumab |
1442657-12-6 |
详细
|
| Begelomab |
Begelomab |
1403744-56-8 |
详细
|
| BLU-945 |
BLU-945 |
2660250-10-0 |
详细
|
| SW-033291 |
SW033291 |
459147-39-8 |
详细
|
| Daprodustat;GSK1278863 |
达普司他 |
960539-70-2 |
详细
|
| Idarucizumab |
Idarucizumab |
1362509-93-0 |
详细
|
| Aducanumab |
阿杜那单抗 |
1384260-65-4 |
详细
|
| Bimekizumab |
BIMEKIZUMAB |
1418205-77-2 |
详细
|
| Guselkumab |
古塞库单抗 |
1350289-85-8 |
详细
|
| Tosatoxumab |
Tosatoxumab |
1374419-41-6 |
详细
|
| Bococizumab |
Bococizumab |
1407495-02-6 |
详细
|
| Vanucizumab |
Vanucizumab |
1448221-05-3 |
详细
|
| Vitamin K2 (Mk7) |
维生素K2 MK7 |
2124-57-4 |
详细
|
| GW2580 |
GW2580 |
870483-87-7 |
详细
|
| Vidofludimus;4SC-101 |
维多氟拉迪莫 |
717824-30-1 |
详细
|
| Stattic |
Stattic |
19983-44-9 |
详细
|
| AZD9496 |
(E)-3-[3,5-二氟-4-[(1R,3R)-2-(2-氟-2-甲基丙基)-3-甲基-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-1-基]苯基]丙烯酸 |
1639042-08-2 |
详细
|
| ON123300 |
8-环戊基-7,8-二氢-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-7-氧代-吡啶并[2,3-D]嘧啶-6-甲腈 |
1357470-29-1 |
详细
|
| CC122 |
3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4H)-基)哌啶-2,6-二酮 |
1015474-32-4 |
详细
|
| BMS-986165 |
BMS-986165 |
1609392-27-9 |
详细
|
| Otlertuzumab |
Otlertuzumab |
1372645-37-8 |
详细
|
| Go 6983 |
3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮 |
133053-19-7 |
详细
|
| Sofituzumab Vedotin |
Sofituzumab Vedotin |
1418200-58-4 |
详细
|
| Ontuxizumab |
Ontuxizumab |
946415-62-9 |
详细
|
| Remtolumab |
壬托鲁单抗 |
1791410-27-9 |
详细
|
| Evinacumab |
Evinacumab |
1446419-85-7 |
详细
|
| 3-Piperidinecarboxamide, N-(4,6-difluoro-2-benzothiazolyl)-1-[2-(dimethylamino)ethyl]- |
化合物MCUF-651 |
2747162-85-0 |
详细
|
| WP 1066 |
(2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺 |
857064-38-1 |
详细
|
| BAY-57-1293;Pritelivir |
普瑞利韦 |
348086-71-5 |
详细
|
| Tazemetostat (EPZ-6438) |
EPZ-6438 |
1403254-99-8 |
详细
|
| BLU-9931 |
BLU 9931 |
1538604-68-0 |
详细
|
| Durvalumab |
德瓦鲁单抗 |
1428935-60-7 |
详细
|
| Atezolizumab |
阿特珠单抗 |
1380723-44-3 |
详细
|
| Varlilumab |
伐立鲁单抗 |
1393344-72-3 |
详细
|
| dinutuximab |
dinutuximab |
1363687-32-4 |
详细
|
| UCB-9260 |
UCB-9260 |
1515888-53-5 |
详细
|
| Vantictumab |
万替妥单抗 |
1345009-45-1 |
详细
|
| Lifastuzumab Vedotin |
Lifastuzumab Vedotin |
1401812-88-1 |
详细
|
| Lulizumab Pegol |
Lulizumab Pegol |
1421830-13-8 |
详细
|
| Imalumab |
Imalumab |
1430205-07-4 |
详细
|
| PD 123319 ditrifluoroacetate |
PD 123319 二(三氟乙酸盐) |
136676-91-0 |
详细
|
| SB 742457 |
3-苯基磺酰基-8-(哌嗪-1-基)喹啉 |
607742-69-8 |
详细
|
| SH-4-54 |
SH-4-54 |
1456632-40-8 |
详细
|
| Vobarilizumab |
Vobarilizumab |
1628814-88-9 |
详细
|
| Codrituzumab |
考曲妥珠单抗 |
1365267-33-9 |
详细
|
| Margetuximab |
玛格妥昔单抗 |
1350624-75-7 |
详细
|
| Abrilumab |
阿利鲁单抗 |
1342290-43-0 |
详细
|
| Emactuzumab |
Emactuzumab |
1448221-67-7 |
详细
|